Actual Weight To Calculate Surface Area Provides The Best Estimate Of AUC For Melphalan In Myeloma  by Shaw, P.J. et al.
S180 Oral Presentations66
ACTUAL WEIGHT TO CALCULATE SURFACE AREA PROVIDES THE BEST
ESTIMATE OF AUC FOR MELPHALAN IN MYELOMA
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Kwan, Y.-L.2, Presgrave, P.4, Tiley, C.R.5, Joshua, D.E.6,7,
Kerridge, I.H.3, McLachlan, A.J.2,7, Earl, J.W.1 1Children’s Hospital
at Westmead, Sydney, NSW, Australia; 2Concord Hospital; 3Westmead
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High dose melphalan (MLP, 200 mg/m2) is an important treat-
ment for multiple myeloma, even in the era of novel biological
agents. The prevalence of obesity is increasing, but there is little in-
formation on how best to adjust the dose in obese patients.
Aim:Use pharmacokinetic data from 16 lean patients (body mass in-
dex, BMI# 25 kg/m2) and 36 obese patients (BMI$ 30 kg/m2) with
normal renal function (est Cr Cl. 60 mL/min) to evaluate alternate
size descriptors that best fit the actual drug exposure.
Methods: PlasmaMLP levels were measured in 6-12 blood samples
collected from 100 patients who had received a single high dose of
MLP (median:192 mg/m2). Individual results of MLP clearance
were determined using a two compartment model developed using
the NONMEM IV software. Subsequent analysis was restricted to
obese and lean patients with normal renal function. Two-sided
two-sample T-test was first used to compare MLP clearance of
lean and obese patients. Extrapolating from individual clearance
results, drug exposure (AUC) for obese patients (AUCobese) was pre-
dicted using the formula dose/clearance, where dose was calculated
either using actual body weight (ABW) in the formula for BSA or
alternate weight descriptors. The AUC for lean patients (AUClean)
used ABW in the BSA formula. The ratio of AUCobese: mean
AUClean was calculated and compared to unity (indicating equivalent
exposure for obese and lean patients) using a two-sided, one-sample
T-test. This analysis was repeated for each gender separately.
Results: MLP Clearance (L/h) is significantly higher in obese pa-
tients compared with lean patients (32.26 10.2 versus 26.16 6.2
L/h, p\0.05), but after normalisation to BSA using ABW, there is
no significant difference (15.96 4.8 versus 15.26 3.3 L/h/m2). Us-
ing ABW in the BSA formula to determine dose, AUCobese is (mean
6 s.d.) 13.66 3.9 mg/L.h, AUClean is 13.86 2.9 mg/L.h, resulting
in a ratio of 0.996 0.29, which is not significantly different from
1.0. All other weight descriptors in the BSA formula (predicted nor-
mal weight, ideal body weight, adjusted ideal body weight, lean body
mass and the mean of ideal and ABW) resulted in AUC ratios that
were significantly lower than 1.0 (p\0.05).
Conclusions: Use of ABW in the BSA formula to calculate dose
rather than alternate weight descriptors achieves equivalent exposure
to MLP in obese and lean patients. Continued follow up will assess
the significance of these levels in all weight groups.PEDIATRIC DISORDERS
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INTERNATIONAL MULTICENTER STUDY ANALYZING THE LONG TERM
OUTCOME OF HURLER SYNDROME PATIENTS AFTER SUCCESSFUL HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION
Aldenhoven, M.1, de Koning, T.J.2, Wraith, E.J.3, Wynn, R.F.4,
Boelens, J.J.1 1University Medical Center Utrecht, Netherlands; 2Uni-
versity Medical Center Utrecht, Netherlands; 3Royal Manchester Child-
ren’s Hospital, Manchester, United Kingdom; 4Royal Manchester
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Hurler syndrome (HS), the most severe phenotype in the spec-
trum of Mucopolysaccharidosis type I (MPS I), is caused by a severe
deficiency of the lysosomal enzyme alpha-L-iduronidase (IDUA).
HS is clinically characterized by a progressive and ultimately fatal
multi-system deterioration with involvement of the central nervous
system. At present, hematopoietic stem cell transplantation
(HSCT) is the only treatment able to prevent disease progression
in the central nervous system and therefore considered the treatment
of choice in HS.Successful donor engraftment in HS patients has shown to be
highly effective, although with variable outcome between trans-
planted patients. Since long term follow-up data are sparse, insight
in the long term outcome of successfully transplanted HS patients
and the influencing factors are still largely unknown. Recently, an in-
ternational multicenter study has been initiated analyzing the long
term outcome of successfully transplanted HS patients worldwide.
The primary outcome parameters consist of the neurocognitive/de-
velopmental and functional outcome. Secondary outcome parame-
ters include the outcome regarding the various organ systems (eg
orthopedic, cardiac, respiratory, ophthalmologic, etc) as well as the
quality of life and processes of care. This international study will in-
clude ‘alive and engrafted’ HS patients, with a follow up of at least
three years post-HSCT. These patients, approximately 200 (about
80% of the HS patients successfully transplanted worldwide), have
been transplanted between 1980 and 2006 at the leading transplan-
tation centers in Europe as well as theUnited States. From eight cen-
ters, with a total of 160 patients by the end of 2009, data collection is
already achieved. An update of the study will be presented during the
meeting.
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CHILDREN WITH HURLERS SYNDROME AFTER MYELO-ABLATIVE CON-
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Hurlers syndrome (HS), the most severe form of mucopolysac-
charidosis type-I causes progressive deterioration of the central
nervous system and death in childhood. Allogeneic-stem cell trans-
plantation (SCT), if performed early halts disease progression and
prolongs life. Graft-failure and mixed-chimerism (40-50%) limit
the success of SCT in HS. Various cell sources including unrelated
cord blood have been used over the last decades. However, impact
of various cell sources (Matched Sibling donor; MSD, unrelated
donor; UD, unrelated cord blood; uCB and T-cell depleted UD;
TCDud) on outcomes of SCT in HS is not well studied. We have
analyzed 258 HS children that received a SCT after a myelo-ablative
conditioning regimen from 1995 to 2007 and were reported to
EUROCORD, EBMT or CIBMTR. Median age at SCT was 16.7
(2-228) months, and median follow up was 57 (1.3-140) months.
The donors were MSD (n5 37; 14%), UD (n5 52; 21%), uCB
(n5 116; 44%), TCDud (n5 53; 21%). All but 8 patients, received
a Busulfan-based myeloablative regimen. All patients receiving an
unrelated donor and 8 MSD received ATG (n5 207) or Campath
(n5 21).
Overall neutrophil recovery was 91+/-3% at day 60. Overall acute-
GvHD (grade II-IV) was observed in 26%, while chronic-GvHD
was seen in 12+/-3% at 5 years. Five years overall survival (OS)
and disease and event free survival (EFS) were 74% and 64%, respec-
tively. ForOS at 5 years, an age of\20months at SCTwas associated
with a higher survival (p5 0,04). OS was higher after MSD (92%),
compared to the other sources UD (76%; p5 0.078), uCB (74%;
p5 0,038) and TCDud (64%; p5 0,007). EFS at 5 years was similar
between MSD (81%), MUD (69%; p5 0,148) and uCB (67%;
p5 0,11) but lower after TCDud (38%; p\0.001). Of those who
